Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jonathan Ginns

Adult Congenital Heart Disease Austin, TX Medical Doctor

NPI 1962737692 CMS profile 589728

900 W 38Th St Ste 400, Austin, TX 78705

Open in the dashboard

General payments

$116,958

202 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$96,662 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Jonathan Ginns of Austin, TX is reported in the CMS Open Payments database as having received $116,958 across 202 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $96,662 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $66,511 58
2024 General $20,382 50
2023 General $24,252 42
2022 General $4,898 24
2021 General $848 24
2020 General $67 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Ginns
  • Adult Congenital Heart Disease median
  • Middle half of Adult Congenital Heart Disease
  • National median

In program year 2025, general payments to Jonathan Ginns were reported at $66,511. Among 56 Adult Congenital Heart Disease profiles paid that year, the median was $272 and the middle half received between $51 and $642.

Show as a table
Year Jonathan Ginns Adult Congenital Heart Disease median Middle half National median
2019 $0 $202 $71–$498 $163
2020 $67 $127 $28–$236 $114
2021 $848 $138 $34–$310 $132
2022 $4,898 $275 $125–$1,572 $149
2023 $24,252 $215 $58–$1,454 $160
2024 $20,382 $273 $84–$801 $164
2025 $66,511 $272 $51–$642 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. E.R. Squibb & Sons, L.L.C. $112,609 88 payments
  2. Abbott Laboratories $1,956 34 payments
  3. Celgene Corporation $300 1 payment
  4. Pfizer Inc. $276 10 payments
  5. Novartis Pharmaceuticals Corporation $271 15 payments
  6. CVRx, Inc. $244 8 payments
  7. Alnylam Pharmaceuticals Inc. $215 8 payments
  8. Abiomed $170 3 payments
  9. Medtronic, Inc. $166 1 payment
  10. Bayer HealthCare Pharmaceuticals Inc. $152 7 payments
  11. Other $599 27 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $86,214 20 payments
  2. Travel and Lodging $22,312 18 payments
  3. Food and Beverage $6,633 158 payments
  4. Consulting Fee $1,800 6 payments
Products named General payments · program years 2020–2025
  1. CAMZYOS $111,378 82 payments
  2. CARDIOMEMS Heart failure $495 14 payments
  3. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $470 7 payments
  4. Barostim Neo System $244 8 payments
  5. ENTRESTO $225 13 payments
  6. VYNDAQEL $222 7 payments
  7. ONPATTRO $215 8 payments
  8. CARDIOMEMS Neuromodulation $192 1 payment
  9. Impella $170 3 payments
  10. COREVALVE EVOLUT R $166 1 payment
  11. Other $1,749 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,554

Prescriptions dispensed, refills included

Drug cost

$309,739

Paid at the pharmacy, in all

Branded share of claims

8.5%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 88 $118,857
Camzyos Mavacamten Brand 11 $91,915
Xarelto Rivaroxaban Brand 19 $29,640
Entresto Sacubitril/Valsartan Brand 26 $26,134
Repatha Sureclick Evolocumab Brand 21 $16,652
Atorvastatin Calcium Generic 370 $3,593
Metoprolol Succinate Generic 199 $3,240
Rosuvastatin Calcium Generic 236 $3,227
Losartan Potassium Generic 191 $2,306
Ezetimibe Generic 102 $1,941

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$228,194

Medicare's payments for the services billed

Medicare patients

936

Average age 76

Services billed

3,049

396 women, 540 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 68%
Atrial fibrillation 51%
Heart failure 44%
Arthritis 42%
Diabetes 31%
Chronic kidney disease 31%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $19,563
$19,563 11 —
Ozempic
  • Novo Nordisk Inc $68
$68 — —
VYNDAQEL
  • PFIZER INC. $40
$40 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $26
$26 — —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Congenital Heart Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record